STAMFORD, Conn., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. CARA, a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists' annual meeting, to be held October 21-25, 2017 in Boston.
Presentations will include clinical trial data for CR845, Cara's first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
Details for the presentations are as follows:
| CR845 Oral Abstract Presentation: | |
| Title: | "Respiratory Effects of I.V. CR845: A Peripherally Acting, Selective Kappa Opioid Receptor Agonist" |
| Abstract Number: | JS01 |
| Date / Time: | Sunday, October 22, 2017; 9:00 a.m. – 12:00 p.m. ET |
| Presenter: | Eugene Viscusi, M.D., Director, Acute Pain Management, Thomas Jefferson University |
| Satellite Symposium: | |
| Title: | "A Potential New Path to Pain Relief: Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)" |
| Date / Time: | Sunday, October 22, 2017; 7:00 – 8:00 a.m. ET |
| Presenters: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
| Christopher L. Wu, M.D., Professor, Division of Obstetric Anesthesiology, Division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, The Johns Hopkins Hospital | |
For information about ANESTHESIOLOGY® 2017, visit www.asahq.org/annualmeeting.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
